Business Wire

NTT: World's Largest Capacity of 1.2 Tbit/s Per Wavelength Achieved by Newly Developed Digital Coherent Signal Processing Circuit and Optical Device

Share

NTT Corporation (NTT, Head office: Chiyoda-ku Tokyo; President & CEO: Akira Shimada) has developed a digital coherent signal processing circuit and optical device that achieves the world's largest capacity of 1.2 Tbit/s per wavelength for optical transmission, which is 1.5 times faster than before. With this development, NTT tackles the challenge of achieving advanced optical transmission technology that can economically and significantly expand the capacity of existing systems while reducing the power consumption of communication devices.

The technology has also achieved the world’s highest optical signal modulation speed of 140 Giga baud and enables double the previous world record optical transmission distance of 800 Gbit/s. As a result, the capacity of optical transmission systems will increase by 12 times and the power consumption per bit will be reduced to 10% of the widely used commercial system. The improvements in the performance and power consumption of optical transmission systems should contribute to the All-Photonics Network foundational to the IOWN1 concept.

Our digital coherent signal processing circuit combines cutting-edge coded modulation with transmission performance approaching the theoretical limit and newly developed forward error correction that can correct bit errors in large amounts of data with low power consumption. This results in flexible coded modulation that maximizes the potential of high-speed optical devices. Furthermore, by utilizing a power-efficient algorithm to equalize signal distortion in the optical fiber transmission channel and the advanced CMOS processes, we have achieved a digital signal processing of 1.2 Tbit/s per wavelength with low power consumption.

The transceiver consists of a cutting-edge digital coherent signal processing circuit and a 140-Giga baud class optical device with the world's widest-class opto-electrical response bandwidth. In our approach, by increasing the modulation speed from 100 Giga baud to 140 Giga baud, higher resistance to waveform distortion and optical amplification noise caused by transmission could be achieved. As a result, the previous record transmission distance of 800 Gbit/s signals can be extended by more than twice that of the 100 Giga baud devices.

Toward the development of IOWN, NTT aims to create an innovative network with high capacity, low latency, flexibility, and low power consumption by continuing to expand and develop end-to-end photonics technology. We will promote the creation of economical, large-capacity, low-power-consumption networks by leveraging advanced optical transmission systems based on innovative technology. We also intend to collaborate with both international and domestic partners so that our developments can be valuable and beneficial for communities worldwide. You can access the full report about this development here.

1 IOWN: https://group.ntt/jp/newsrelease/2019/05/09/190509b.html (Japanese)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
NTT Corporation
Science and Core Technology Laboratory Group, Public Relations Section
nttrd-pr@ml.ntt.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release

Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release

MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye